Federal health and law enforcement officials are expected to release coordinated operational guidance on Saturday as the practical implications of President Trump's reclassification of state-licensed medical marijuana to Schedule III of the Controlled Substances Act begin to take shape. The Drug Enforcement Administration and the Department of Health and Human Services confirmed late Friday that a joint advisory document would be published to address immediate questions from dispensaries, prescribers, and pharmacists operating across state lines.

The reclassification, announced Thursday, marks the most significant shift in federal cannabis policy in decades, moving medical marijuana out of the most restrictive Schedule I category — which had classified it alongside heroin — to Schedule III, placing it in the same tier as ketamine and certain anabolic steroids. The change carries immediate implications for taxation under IRS Section 280E, insurance reimbursement policies, and the ability of federally licensed healthcare institutions to recommend the drug.

Dispensary operators across states including California, Colorado, Florida, and New York reported being inundated with inquiries from patients and medical professionals throughout Friday, with many seeking clarification on whether existing state medical cards would be recognized under the new federal framework and how prescribers could document recommendations without risking federal licensing complications. Industry groups including the National Cannabis Industry Association called for the Saturday guidance to include a 90-day compliance grace period.

The American Medical Association and the American Pharmacists Association issued a joint statement Friday afternoon welcoming the reclassification while urging caution, noting that clinical protocols for dosing, contraindications, and patient monitoring had not yet been harmonized at the federal level. Both organizations said they would engage with HHS over the coming weeks to develop standardized prescriber education materials.

Health policy analysts noted that the Saturday guidance document, while primarily administrative in nature, would set the tone for how quickly the reclassification translates into tangible access improvements for patients with qualifying conditions such as chronic pain, multiple sclerosis, and chemotherapy-induced nausea. 'The rule change is historic, but the guidance is where the real policy is written,' said one former FDA official familiar with the process. States with existing robust medical marijuana frameworks are expected to move fastest to align their licensing structures with the new federal designation.